Haadi Ali, MD

University of Michigan

Published Articles (1)

Gastrointestinal Cancer Updates From the Best of GI Oncology 2026

August 20, 2026

Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.